JP2007506748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506748A5 JP2007506748A5 JP2006528110A JP2006528110A JP2007506748A5 JP 2007506748 A5 JP2007506748 A5 JP 2007506748A5 JP 2006528110 A JP2006528110 A JP 2006528110A JP 2006528110 A JP2006528110 A JP 2006528110A JP 2007506748 A5 JP2007506748 A5 JP 2007506748A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- methyl
- methoxy
- dihydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 206010003119 arrhythmia Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 230000005764 inhibitory process Effects 0.000 claims 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 2
- 206010003662 Atrial flutter Diseases 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- WNSFBSVZSFGWKG-UHFFFAOYSA-N 2-cyclopropyl-6-methoxy-4-phenyl-3-(1,3-thiazol-2-yl)isoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C2CC2)C=2C=3SC=CN=3)=O)C=1C=2C1=CC=CC=C1 WNSFBSVZSFGWKG-UHFFFAOYSA-N 0.000 claims 1
- QPSHMPFUHZJDOG-UHFFFAOYSA-N 4-(3-fluorophenyl)-6-methoxy-2-methyl-3-(pyrrolidine-1-carbonyl)isoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C(=O)N3CCCC3)=O)C=1C=2C1=CC=CC(F)=C1 QPSHMPFUHZJDOG-UHFFFAOYSA-N 0.000 claims 1
- BPWTXMARXPIAPN-UHFFFAOYSA-N 4-(3-fluorophenyl)-6-methoxy-n,n,2-trimethyl-1-oxoisoquinoline-3-carboxamide Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C(=O)N(C)C)=O)C=1C=2C1=CC=CC(F)=C1 BPWTXMARXPIAPN-UHFFFAOYSA-N 0.000 claims 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 1
- HQHWFQBVHGZPDU-UHFFFAOYSA-N 6-methoxy-2-methyl-4-phenyl-3-pyridin-2-ylisoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C=3N=CC=CC=3)=O)C=1C=2C1=CC=CC=C1 HQHWFQBVHGZPDU-UHFFFAOYSA-N 0.000 claims 1
- LVYBSQBIEGOECD-UHFFFAOYSA-N 7-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylic acid Chemical compound OC(=O)C=1N(C)C(=O)C2=CC(OC)=CC=C2C=1C1=CC=CC=C1 LVYBSQBIEGOECD-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 claims 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229940127449 Integrin Receptor Antagonists Drugs 0.000 claims 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 claims 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 claims 1
- 108091007262 P2T receptors Proteins 0.000 claims 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- -1 factor Xa inhibitors Substances 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- JHHCUIOLGXFAFI-UHFFFAOYSA-N methyl 4-(3-fluorophenyl)-6-methoxy-2-methyl-1-oxoisoquinoline-3-carboxylate Chemical compound C12=CC(OC)=CC=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC(F)=C1 JHHCUIOLGXFAFI-UHFFFAOYSA-N 0.000 claims 1
- CUTKKQAWWOLGDB-UHFFFAOYSA-N methyl 6-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylate Chemical compound C12=CC(OC)=CC=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC=C1 CUTKKQAWWOLGDB-UHFFFAOYSA-N 0.000 claims 1
- OAHAJCKNSCXKLU-UHFFFAOYSA-N methyl 7-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylate Chemical compound C12=CC=C(OC)C=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC=C1 OAHAJCKNSCXKLU-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 150000008143 steroidal glycosides Chemical class 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 229960005001 ticlopidine Drugs 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50513803P | 2003-09-23 | 2003-09-23 | |
| US60/505,138 | 2003-09-23 | ||
| PCT/US2004/030944 WO2005030727A1 (en) | 2003-09-23 | 2004-09-22 | Isoquinolinone potassium channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007506748A JP2007506748A (ja) | 2007-03-22 |
| JP2007506748A5 true JP2007506748A5 (https=) | 2007-08-02 |
| JP4719152B2 JP4719152B2 (ja) | 2011-07-06 |
Family
ID=34392983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528110A Expired - Fee Related JP4719152B2 (ja) | 2003-09-23 | 2004-09-22 | イソキノリノンカリウムチャネル阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7781457B2 (https=) |
| EP (1) | EP1667977A4 (https=) |
| JP (1) | JP4719152B2 (https=) |
| CN (1) | CN1856473A (https=) |
| AU (1) | AU2004276267B2 (https=) |
| CA (1) | CA2539541C (https=) |
| WO (1) | WO2005030727A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030726A1 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| JP4719151B2 (ja) * | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノンカリウムチャネル阻害剤 |
| WO2005030791A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| EP1667981A4 (en) * | 2003-09-23 | 2008-08-13 | Merck & Co Inc | ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS |
| US7879839B2 (en) | 2004-07-29 | 2011-02-01 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
| WO2007121453A2 (en) * | 2006-04-17 | 2007-10-25 | The Regents Of The University Of California | 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents |
| RU2436577C2 (ru) * | 2006-04-27 | 2011-12-20 | Санофи-Авентис Дойчланд Гмбх | Ингибиторы ионных task-1 и task-3 каналов |
| DE102006019589A1 (de) * | 2006-04-27 | 2007-10-31 | Sanofi-Aventis Deutschland Gmbh | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
| EP2511266B1 (en) | 2006-07-10 | 2019-09-04 | The Regents of The University of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| ES2475193T3 (es) | 2007-01-22 | 2014-07-10 | Gtx, Inc. | Agentes de unión al receptor nuclear |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2010039534A2 (en) * | 2008-09-23 | 2010-04-08 | Georgetown University | Viral and fungal inhibitors |
| US8563580B2 (en) | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| EP2816038B8 (en) | 2009-08-24 | 2019-12-25 | Lumiphore, Inc. | Hopo chelators |
| MX2013002295A (es) * | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
| CN103864684A (zh) * | 2012-12-07 | 2014-06-18 | 天津科技大学 | 一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用 |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69110828T2 (de) * | 1990-10-16 | 1995-11-30 | Takeda Chemical Industries Ltd | Heterozyklische Aminderivate, deren Herstellung und deren Verwendung. |
| TW241258B (https=) * | 1992-04-15 | 1995-02-21 | Takeda Pharm Industry Co Ltd | |
| EP0585913B1 (en) * | 1992-09-04 | 1997-12-29 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
| TW263498B (https=) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| JPH10298164A (ja) * | 1997-02-27 | 1998-11-10 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体、その製法及びその合成中間体 |
| WO1998038168A1 (en) * | 1997-02-27 | 1998-09-03 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
| JP2000072751A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体 |
| US6444685B1 (en) * | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| EP1322619B1 (en) * | 2000-09-20 | 2008-01-23 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| CN1500080A (zh) | 2001-02-02 | 2004-05-26 | ����ҩƷ��ҵ��ʽ���� | 稠合杂环化合物 |
| AU2003211931A1 (en) * | 2002-02-13 | 2003-09-04 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| JP4719151B2 (ja) * | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノンカリウムチャネル阻害剤 |
| WO2005030726A1 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| EP1667981A4 (en) * | 2003-09-23 | 2008-08-13 | Merck & Co Inc | ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS |
| WO2005030791A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
-
2004
- 2004-09-22 CN CNA2004800273785A patent/CN1856473A/zh active Pending
- 2004-09-22 CA CA2539541A patent/CA2539541C/en not_active Expired - Fee Related
- 2004-09-22 EP EP04788883A patent/EP1667977A4/en not_active Withdrawn
- 2004-09-22 JP JP2006528110A patent/JP4719152B2/ja not_active Expired - Fee Related
- 2004-09-22 WO PCT/US2004/030944 patent/WO2005030727A1/en not_active Ceased
- 2004-09-22 AU AU2004276267A patent/AU2004276267B2/en not_active Ceased
- 2004-09-22 US US10/572,343 patent/US7781457B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506748A5 (https=) | ||
| JP2007516218A5 (https=) | ||
| JP2007506742A5 (https=) | ||
| WO2008073392A3 (en) | Compositions and methods for cardiac tissue protection and regeneration | |
| CA2539814A1 (en) | Isoquinolinone potassium channel inhibitors | |
| JP2007511487A5 (https=) | ||
| CN104147010A (zh) | 治疗心房颤动的方法 | |
| JP2004533464A5 (https=) | ||
| CA2539541A1 (en) | Isoquinolinone potassium channel inhibitors | |
| HK1052170A1 (zh) | 新型化合物抑制因子xa活度 | |
| NO20070148L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
| JP2007527904A5 (https=) | ||
| ES2296964T3 (es) | Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares. | |
| WO2009114716A3 (en) | Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling | |
| NO20070147L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
| KR100907584B1 (ko) | 굴심방 결절 Ｉｆ 전류 억제제 및 칼슘채널억제제의 회합체 및 이를 함유하는 약제 조성물 | |
| RU2004136583A (ru) | Применение валсартана или его метаболита для ингибирования агрегации тромбоцитов | |
| WO2008091618A8 (en) | Use of d-ribose to treat cardiac arrhythmias | |
| MY138896A (en) | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | |
| JP2007527903A5 (https=) | ||
| JP6336484B2 (ja) | 遅延ナトリウム電流遮断薬および洞房結節ｉｆ電流阻害薬の組合せ、ならびに該組合せを含む医薬組成物 | |
| Pinter et al. | New approaches to atrial fibrillation management: treat the patient, not the ECG | |
| RU2005119970A (ru) | Оптически активное производное дигидропиридина | |
| JP2008516952A5 (https=) | ||
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |